Almac Sciences and BioCatalytics to co-operate on key pharma products
UK-based Almac Sciences has signed a key chiral technology agreement with US company BioCatalytics, a leading global player in enzyme catalyst technologies.
UK-based Almac Sciences has signed a key chiral technology agreement with US company BioCatalytics, a leading global player in enzyme catalyst technologies.
Under the agreement the two companies will co-operate on an exclusive basis in the development of processes and manufacture of a group of chiral intermediates and APIs. Clinical phase and launched products are covered at all scales.
Almac Sciences will scale up and embed BioCatalytics' technology in a range of 'manufacturing solutions', in line with its supply chain solutions and virtual manufacturing business model. 'Chirality is already a major strength within our portfolio of connectable drug development and commercialisation services,' said Dr David Moody, vp commercial operations. 'The ability to develop and apply BioCatalytics' excellent chiral technology is a significant addition to our portfolio.'
BioCatalytics' president and ceo David Rozzell added: 'We look forward to working with Almac Sciences to commercialise processes using our proprietary enzymatic systems. Through this partnership customers will gain the benefit of BioCatalytics' broad enzyme technology coupled with Almac's manufacturing expertise for the production of key chiral intermediates and APIs.'
The technology agreement with BioCatalytics is the latest in a series by Almac Sciences to connect with key technologies. The company recently announced a collaboration with the University of Kentucky's Center for Pharmaceutical Science and Technology (CPST) for cytoxic fill and finish services for clinical trial applications.
